Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies

Abstract excerpt

Cancer drugs that target pivotal signaling molecules required for malignant cell survival and growth have demonstrated striking antitumor activities in appropriately selected patient populations. Unfortunately, however, therapeutic responses are often of limited duration, typically 6-12 months, because of emergence of drug-resistant subclones of tumor cells. In this review, we highlight several of the mechanisms...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Melanoma and MAPK Pathways
• Share to PI3K/AKT/mTOR signaling in cancer